Clinical Trial

OJO-miR: microRNA Expression in Allergic Conjunctivitis.

Study acronym: OJO-miR
Active, Not Recruiting
View on ClinicalTrials.gov →
Summary
Allergic conjunctivitis (AC) causes inflammation of the conjunctiva in response to environmental allergens, affecting a significant percentage of the world population and reducing quality of life. The pathophysiology is poorly understood, lacking effective treatments. MicroRNAs have potential for diagnosing and characterizing inflammatory diseases. This study aims to compare the expression profiles of inflammation-regulating microRNAs (miR-19, miR-23, miR-125b, miR-146a, and miR-155) in serum and tear samples from subjects with AC and healthy subjects to identify biomarkers and therapeutic targets.
Trial Details
NCT Number NCT07385495
Lead Sponsor Instituto de Oftalmología Fundación Conde de Valenciana
Conditions Conjunctivitis, Allergic
Enrollment 40 participants
Start Date 2026-01-05
Primary Completion 2027-01-05 (estimated)
Study Completion 2027-07-05 (estimated)
Updated on ClinicalTrials.gov 2026-02-04